6 November 2014

Share Purchase Plan Acceptances

Antisense Therapeutics Limited ("ANP" or "the Company") advises that it has received valid application monies from Shareholders of $269,990 pursuant to the Share Purchase Plan (SPP) announced to the ASX on 25 September 2014. The SPP was underwritten to an amount of $1,000,000 and the shortfall from the issue has been placed in accordance with the terms of the underwriting agreement between the Company and the underwriter, Patersons Securities Limited.

A total of 8,695,652 Shares will be issued under the SPP. The Shares will be allotted and holding statements dispatched to Shareholders on 12 November 2014.

The SPP follows a $1,000,000 share placement to sophisticated and professional investors, which was oversubscribed. Funds raised pursuant to the share placement, SPP and recently received R&D Tax incentive refund of $1,140,000 will be utilised to support ongoing partnering interactions and a planned higher dose clinical trial of ATL1103 in acromegalic patients.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999
Australian Investor/Media: Annabel Murphy+61 (0)2 9237 2800; amurphy@buchanwe.com.au

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) , ATL1103 a second-generation antisense drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.